Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
Lisata Therapeutics, Inc. LSTA
$1.02
▼ -8.93%
($-0.10)
🎈 Low Float
Open
$1.09
Prev Close
$1.12
Day Range
$1.01 – $1.09
52W Range
$0.96 – $5.07
Market Cap
$12.10M
Beta
1.03
EPS (TTM)
$-1.14
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1995-11-03 |
| Shares Out. | 10,800,000 |
| Website | lisata.com ↗ |
| Phone | 13028948922 |
| Employees | 21 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$2.9M |
| Free Cash Flow | -$12.3M |
| Total Assets | $11.0M |
| Total Liabilities | $3.0M |
| Equity | $8.0M |
About Lisata Therapeutics, Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Lisata Therapeutics, Inc. is a publicly traded company under the ticker symbol LSTA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)